Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €63.02 EUR
Change Today -1.08 / -1.69%
Volume 0.0
QTS On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 11:17 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

quintiles transnational hold (QTS) Snapshot

Open
€64.28
Previous Close
€64.10
Day High
€64.28
Day Low
€63.00
52 Week High
05/26/15 - €64.60
52 Week Low
05/30/14 - €36.76
Market Cap
7.7B
Average Volume 10 Days
16.6
EPS TTM
--
Shares Outstanding
122.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUINTILES TRANSNATIONAL HOLD (QTS)

quintiles transnational hold (QTS) Related Businessweek News

No Related Businessweek News Found

quintiles transnational hold (QTS) Details

Quintiles Transnational Holdings Inc., through its subsidiary, Quintiles Transnational Corp., provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through two segments, Product Development and Integrated Healthcare Services. The Product Development segment offers project management and clinical monitoring services, including study design and operational planning, investigator/site recruitment, site and regulatory start up, patient recruitment, clinical monitoring, and project management for conducting various multi-site trials; and clinical trial support services comprising clinical data management, biostatistical, central laboratories, genomic laboratory, bioanalytical laboratories, cardiac safety and ECG, safety and pharmacovigilance, and phase I clinical pharmacology services. This segment also provides strategic planning and design services for biomarkers, genomics, and personalized medicine, as well as offers model-based drug development and regulatory affairs services; and consulting services, such as product development strategy, regulatory and compliance, and process and IT implementation consulting services. The Integrated Healthcare Services segment offers commercial services comprising contract sales, market entry/market exit, integrated channel management, patient engagement, and market access and commercialization consulting services; real-world late phase services, such as observational studies, comparative effectiveness studies, and product and disease registry services; and communication and health engagement services, including digital patient, and brand and scientific communications services. The company serves biopharmaceutical companies, including medical device and diagnostics companies. Quintiles Transnational Holdings Inc. was founded in 1982 and is based in Durham, North Carolina.

32,600 Employees
Last Reported Date: 03/16/15
Founded in 1982

quintiles transnational hold (QTS) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.0M
Executive Chairman
Total Annual Compensation: $800.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $580.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $434.4K
Compensation as of Fiscal Year 2014.

quintiles transnational hold (QTS) Key Developments

Quintiles Officially Opens Greater China Regional Headquarters in Shanghai

Quintiles announced officially opening the Quintiles Greater China Regional Headquarters, further expanding its ability to help Chinese companies expand globally and multinational companies succeed in the world’s second large biopharmaceutical market. The event comes 17 years after Quintiles first opened an office in Shanghai. Quintiles’ 4,000-square-meter (43,000 square feet) headquarters in Shanghai’s Feng Lin Science Park now has almost 300 employees and is designed to host 450.

Quintiles Launches New Solution to Meet Needs of Asia-Pacific Emerging Biopharmaceutical Companies

Quintiles launched a new solution set tailored to meet the needs of emerging companies in the world’s more diverse and dynamic healthcare market. The Quintiles Asia-Pacific Emerging Biopharma solution includes: Dedicated local project leadership based in Asia-Pac with knowledge of local markets, customs and language; Custom-tailored operational models to meet individual customer priorities and use the company’ world-class processes and platforms; Accelerated patient recruitment through the company’s global network of 25 Prime and greater than 1,200 Partner sites with seven of those Prime Sites located in Asia-Pacific. The Asia-Pacific solution gives emerging companies access to Quintiles’ data-driven insights; its knowledge of local markets; its in-depth therapeutic and scientific expertise; and its global drug development platform. It further adds to Quintiles’ solutions for emerging companies, which includes Novella Clinical, a specialty CRO focused on the needs of small to mid-sized oncology companies and medical device and diagnostic companies.

Quintiles Transnational Holdings Inc. Announces Board Changes

On May 7, 2015, Quintiles Transnational Holdings Inc. received notice that Christopher R. Gordon, a Bain Capital Board designee, and Fred E. Cohen, M.D., D.Phil., F.A.C.P., a TPG Funds Board designee, will both resign as directors effective at the close of the November 2015 Meeting. Notice of Mr. Gordon’s resignation and Dr. Cohen’s resignation was made in connection with the orderly transition of the Board to comply with the NYSE independence rules and was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QTS:GR €63.02 EUR -1.08

QTS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $72.59 USD -0.96
IMS Health Holdings Inc $29.62 USD +0.05
INC Research Holdings Inc $33.93 USD +0.46
PAREXEL International Corp $66.54 USD -0.31
PRA Health Sciences Inc $33.01 USD +0.275
View Industry Companies
 

Industry Analysis

QTS

Industry Average

Valuation QTS Industry Range
Price/Earnings 25.9x
Price/Sales 2.1x
Price/Book NM Not Meaningful
Price/Cash Flow 25.0x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUINTILES TRANSNATIONAL HOLD, please visit www.quintiles.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.